Orgasteron

Orgasteron = Metilestrenolona (Spanish “Metilestrenolona”), also known as normethandrone / methylestrenolone (17α-methyl-19-nortestosterone). 

However, sometimes “Orgasteron” is also referenced as a synonym for trestolone acetate (MENT acetate, also called Orgasteron acetate in some sources) 

Because this is a somewhat obscure / experimental compound, formal clinical data are limited. Below is a summary of what is known (and what is speculative / based on analogies).

---

Identity and Mechanism

Chemical / Alternate Names

• Metilestrenolona / normethandrone / methylestrenolone: a 17α-methylated derivative of 19-nortestosterone (i.e., a methylated nandrolone-type structure). 

• Orgasteron is one of its trade / brand names.

• In some contexts, “Orgasteron acetate” is used as a synonym or confusion with trestolone acetate (MENT acetate). 

• Trestolone (MENT) is 7α-methyl-19-nortestosterone, and its acetate ester is trestolone acetate (MENT acetate, sometimes “Orgasteron acetate”). 

Thus one must be cautious which chemical is referred to when someone says “Orgasteron.”

Pharmacodynamics / Biological Activity

• As a methylated 19-nortestosterone derivative, it is a progestogen / progestin (i.e. binds progesterone receptors) as well as possessing androgenic / anabolic activity (binds androgen receptor).

• It will exert antigonadotropic effects via negative feedback on LH / FSH, thereby suppressing endogenous testosterone production and possibly spermatogenesis. (This is typical of progestogenic AAS) 

• Because of its progestogenic character, it may also influence estrogen / progesterone balance, possibly affect prolactin, and have some “stero­genic / progestational / prolactin-related” actions (see below).

---

Benefits, Uses & Theoretical Pros

Potential benefits (theoretical, experimental, or inferred) include:

• Anabolic / muscle-building: It may promote protein synthesis, nitrogen retention, and muscle growth due to androgen receptor activation (though likely less well studied).

• Progestogenic effects: Could stabilize endometrium, possibly used in gynecological settings (dysmenorrhea, menstrual regulation) historically. (Some early medical usage is reported) 

• Suppression of gonadotropins: This could be leveraged (in theory) for male contraception or therapeutic suppression of hormonal axes. (This is known for related compounds like MENT) 

• Possibly a more favorable anabolic:androgenic ratio than non-nortestosterone 17α-alkylated androgens (i.e. less undesirable androgenic side effects per unit anabolic effect) — but this is speculative / based on limited data.

---

Risks, Side Effects & Theoretical Cons

Because this is a potent steroid / progestin, risks are substantial (many extrapolated from AAS / progestogen knowledge):

• Liver toxicity (hepatotoxicity): 17α-alkylated steroids are notoriously liver-stressing.

• Suppression of endogenous testosterone / testicular atrophy: Via negative feedback on LH/FSH.

• Hormonal imbalance: Because of progestogenic activity, could lead to effects like mood changes, libido changes, menstrual disturbances (in women), and impacts on estrogen / progesterone axis.

• Cardiovascular risks: Dyslipidemia (↓ HDL, ↑ LDL), hypertension, possibly atherosclerosis.

• Androgenic side effects: Acne, seborrhea, hair loss (if genetically predisposed), prostate enlargement or issues (though 19-nor derivatives sometimes have lower DHT conversion).

• Estrogenic / gynecomastia: It may aromatize or be partially converted to estrogenic metabolites, possibly leading to water retention, gynecomastia. Some data suggest that methylated nortestosterones may aromatize to methylestradiol (a potent estrogen) in small amounts. 

• Progestin / prolactin / breast tissue effects: Because progestins can influence prolactin or mammary tissue, there is a risk (theoretical) of progestin-mediated breast effects (though data is limited).

• Other systemic risks: Liver enzyme elevation, renal strain, dermatological effects, suppression of adrenal function, lipid abnormalities, possible cardiovascular strain.

• Reproductive / fertility effects: In men, suppression of spermatogenesis, possible temporary infertility. In women, disruption of menstrual cycles or ovulation.

Because the compound is not well studied, many long-term effects are unknown, making it high risk.

---

Dosage, Frequency, Half-Life & Detection Time

This part is extremely speculative, because formal clinical / pharmacokinetic studies are scarce.

Half-Life & Clearance

• For 7α-methyl-19-nortestosterone (MENT) (i.e. trestolone, close relative), a study showed an average terminal half-life ~ 40 minutes for the non-ester form.

• With the acetate ester (trestolone acetate), some sources (non-peer-reviewed / user forums) claim 8–12 hours half-life. 

• But be cautious: these are approximate and may vary by formulation, dose, species, route of administration, and individual metabolism.

Detection Time

• Because of the limited data, exact detection windows are not reliably known in humans. Some forums / sources claim detection up to 4 weeks for trestolone acetate in bodybuilding / doping settings. 

• But we cannot treat these as scientifically confirmed.

Dosage / Frequency

There is no clinically-approved dosing regimen for “Orgasteron,” so all numbers are speculative (often from anabolic user communities). Use of such is unapproved and risky.

• Some sources suggest “effective dose for men ~ 10 mg/day” for MENT (trestolone) in experimental or prototype regimens. 

• Other (less reliable) sources promoting trestolone acetate claim 50–100 mg per injection every day (ED) or every other day, for 4–10 week cycles. 

• Some product / underground sources list “average cycle: 500–700 mg per week over 4–10 weeks” for trestolone acetate. 

• Because its half-life is short, frequent dosing (daily or every other day) is often cited in underground use. 

• However, these are not medically validated.

In summary: any dose or schedule should be considered highly experimental and dangerous without medical supervision.

---

Anabolic : Androgenic Ratio (A/A Ratio)

• For normethandrone (metilestrenolona / the likely Orgasteron), there is limited direct published data on a precise anabolic:androgenic ratio expressed as a number.

• For normethandrone, one source mentions it “shows a high ratio of anabolic to androgenic activity” relative to some analogues. 

• For trestolone / MENT, some underground / anabolic‐community sources state very high ratios, e.g. “Anabolic rating: 2300, Androgenic rating: 650” (i.e. ~ 3.54 ratio) for a particular trestolone acetate product listing. 

• Also, steroid.com lists for MENT (methylnortestosterone acetate) a purported “anabolic/androgenic ratio: 2300–650” (i.e. ratio ~ 3.54) though this is likely non-peer-reviewed. s

• Thus, the credible scientific literature does not reliably supply a “digit” ratio; those numbers you will see are more from bodybuilding / underground sources than from formal pharmacology studies.

---

Progestogenic / Prolactin / Sterogenic Effects (“Sterogenic / Progestronic Prolactin Effects”)

These terms are somewhat unclear (I interpret “sterogenic / progestinic / prolactin effects”), so I’ll cover possible interactions with progestin and prolactin systems.

• Because Orgasteron (metilestrenolona) is itself a progestin (progestogenic steroid), it can bind progesterone receptors, exert progestational effects (e.g., on uterine lining, supporting pregnancy, altering menstrual cycles). 

• Progestins can sometimes influence prolactin secretion (especially some progestins may increase prolactin) and mammary gland changes, particularly in the presence of estrogen. This may contribute to breast-related side effects or gynecomastia in men (though the magnitude is uncertain).

• Because progestins can modulate estrogen receptor expression, interplay with estrogen and progesterone signaling can affect breast tissue, uterine tissue, and endocrine feedback loops.

• The “stero­genic” aspect may refer to steroidogenic side effects (i.e. influence on steroid hormone synthesis, adrenal, gonadal axis). Because Orgasteron suppresses LH/FSH, endogenous steroid (testosterone, estrogen) synthesis is reduced.

• In sum: Orgasteron, as a progestin‐androgen hybrid, may display both androgenic/anabolic actions and strong progestational / hormonal modulation, and thus risks of prolactin / breast effects are plausible but not well characterized.

---

Summary: Pros & Cons

---

Caveats & Warnings

• Because “Orgasteron / metilestrenolona / normethandrone” is not a widely approved or clinically established drug (at least in many jurisdictions), the data are sparse, and what exists often comes from old reports, animal or in vitro studies, or anecdotal / bodybuilding use.

• Many of the “dosage, half-life, detection, anabolic ratio” figures you will find are from underground / non-peer-reviewed sources and should be treated with skepticism.

• Use of such anabolic / progestogenic steroids, especially unsupervised, carries significant risks to health.

• Always consult endocrinologists / medical professionals in your jurisdiction before considering any such compounds.